NSE close · Tue, 29 SeptNifty 5022,716.20▼ 0.28%Nifty Bank54,259.95▼ 0.39%Midcap 10059,319.40▼ 0.99%Smallcap 25017,747.25▼ 0.65%India VIX13.41▼ 1.69%IT27,670.00▼ 1.48%Auto26,173.35▼ 1.33%Pharma26,933.65▲ 0.64%FMCG44,790.30▼ 1.05%Metal12,954.45▲ 0.78%Realty833.85▼ 2.00%Energy36,509.75▼ 0.50%PSU Bank7,972.80▼ 0.66%Financials24,648.50▼ 0.09%Media1,540.95▲ 0.11%Defence9,139.65▼ 0.99%Durables37,129.95▼ 2.71%Biggest movesDPABHUSHAN▲ 20.0%SYNCOMF▲ 17.9%FERMENTA▲ 15.0%MOMSBELIEF▲ 14.8%KIRLOSENG▲ 12.2%AUGMONT▲ 10.0%AXISCADES▲ 10.0%PRASOLCHEM▲ 10.0%

Top stories

Broker call + Organon · 1 storyClear filters

Developing 127 Picking up 19 Price moves 119 Following

Busiest tags today

AI157 Crude oil118 Global markets111 Nifty and Sensex104 Bond yields99 Market valuations91 Geopolitics81 US Treasuries60 Gold56 Banks55 Iran52 Trade and tariffs52 Wall Street49 Pharma and healthcare45 Every tag in Market pulse →

Company

Organon▲ +33% net tone today

2 stories today · 2 since 29 SeptSun Pharma +1.5% on Tue, 29 Sept

Often with, this weekPharma and healthcare2 Sun Pharma2 Bond yields1 Lerodalcibep1

Open tag page →Clear ×

Broker call▲

Expanding innovative portfolio may drive gains for Sun Pharma stock

Lerodalcibep licensing, US portfolio growth and tariff relief are cited as potential stock drivers
A proposed Organon acquisition could broaden Sun Pharma’s global reach
Potential growth and acquisition catalysts matter to Sun Pharma shareholders

Sun Pharma Lerodalcibep Organon Pharma and healthcare1 source · 4h

That’s everything for today